Should I buy or sell Kura Oncology stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KURA shares. View KURA analyst ratings or view top-rated stocks .

What is Kura Oncology's stock price target for 2024?

8 analysts have issued twelve-month price objectives for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they predict the company's share price to reach $28.28 in the next year. This suggests a possible upside of 63.7% from the stock's current price. View analysts price targets for KURA or view top-rated stocks among Wall Street analysts .

How have KURA shares performed in 2024?

Kura Oncology's stock was trading at $14.38 on January 1st, 2024. Since then, KURA shares have increased by 20.1% and is now trading at $17.27. View the best growth stocks for 2024 here .

When is Kura Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our KURA earnings forecast .

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) issued its earnings results on Tuesday, February, 27th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.01. During the same quarter in the previous year, the business earned ($0.49) earnings per share.

What ETFs hold Kura Oncology's stock?

ETFs with the largest weight of Kura Oncology (NASDAQ:KURA) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH) . ALPS Medical Breakthroughs ETF (SBIO) .

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL) , Inovio Pharmaceuticals (INO) , Viking Therapeutics (VKTX) , SCYNEXIS (SCYX) , VBI Vaccines (VBIV) , Amarin (AMRN) , Gilead Sciences (GILD) , NVIDIA (NVDA) , Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD) .

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.24%) and Saxon Interests Inc. (0.01%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Teresa Brophy Bair, Thomas James Doyle, Thomas Malley and Troy Edward Wilson. View institutional ownership trends .

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KURA

Kura Oncology (KURA) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free KURA Stock Alerts

$17.53

-0.15 (-0.85%)

(As of 04:00 PM ET)

Compare

Today's Range: $16.79
▼
$17.90
50-Day Range: $17.68
▼
$23.53
52-Week Range: $7.41
▼
$24.17

Volume: 1.33 million shs
Average Volume: 1.34 million shs
Market Capitalization: $1.34 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.28

Get Kura Oncology alerts:

Kura Oncology MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 63.7% Upside
$28.28 Price Target
Short Interest: Bearish
16.38% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.76
Upright™ Environmental Score
News Sentiment: 0.47
Based on 3 Articles This Week
Insider Trading: Selling Shares
$1.95 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.35) to ($2.47) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.99 out of 5 stars

Medical Sector

362nd out of 918 stocks

Pharmaceutical Preparations Industry

157th out of 417 stocks

3.4

Analyst's Opinion

Consensus Rating
Kura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Kura Oncology has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
16.38% of the float of Kura Oncology has been sold short.
Short Interest Ratio / Days to Cover
Kura Oncology has a short interest ratio ("days to cover") of 7.4.
Change versus previous month
Short interest in Kura Oncology has recently increased by 1.07%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Kura Oncology does not currently pay a dividend.
Dividend Growth
Kura Oncology does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Kura Oncology is -0.76.

1.4

News and Social Media Coverage

News Sentiment
Kura Oncology has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Kura Oncology this week, compared to 3 articles on an average week.
Search Interest
Only 7 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,946,415.00 in company stock.
Percentage Held by Insiders
Only 5.40% of the stock of Kura Oncology is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Kura Oncology are expected to decrease in the coming year, from ($2.35) to ($2.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kura Oncology is -8.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kura Oncology is -8.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kura Oncology has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Kura Oncology Stock (NASDAQ:KURA)

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

KURA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KURA Stock News Headlines

April 16, 2024 | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Downgraded by StockNews.com to Sell

April 10, 2024 | msn.com

Immunotherapy After Definitive Therapy Flops in Head and Neck Cancer

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 10, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - KURA

April 10, 2024 | globenewswire.com

Kura Oncology to Participate in Stifel Targeted Oncology Forum

April 10, 2024 | globenewswire.com

Kura Oncology to Participate in Stifel Targeted Oncology Forum

April 5, 2024 | globenewswire.com

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 28, 2024 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on Celcuity (CELC)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 7, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Kura Oncology’s KO-2806 Shows Promising Clinical and Market Potential

March 6, 2024 | finanznachrichten.de

Kura Oncology, Inc.: Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

March 6, 2024 | globenewswire.com

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

March 1, 2024 | globenewswire.com

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 1, 2024 | markets.businessinsider.com

Buy Rating for Kura Oncology Amid Strong Q4 Results and Promising Ziftomenib Trials

February 28, 2024 | markets.businessinsider.com

Kura Oncology’s Ziftomenib Shows Promising Clinical Progress with Strong Market Potential and Buy Rating

February 28, 2024 | finance.yahoo.com

KURA Jul 2024 22.500 call

February 28, 2024 | markets.businessinsider.com

Buy Rating for Kura Oncology: Promising Pipeline and Strategic Advantages Solidify Market Position

February 28, 2024 | markets.businessinsider.com

Strong Buy Rating for Kura Oncology Based on Solid Financials and Promising Clinical Trials

February 28, 2024 | markets.businessinsider.com

TD Cowen Sticks to Its Buy Rating for Kura Oncology (KURA)

February 28, 2024 | finance.yahoo.com

Q4 2023 Kura Oncology Inc Earnings Call

February 27, 2024 | seekingalpha.com

Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation

February 27, 2024 | finance.yahoo.com

Kura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial Results

February 27, 2024 | globenewswire.com

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024 | globenewswire.com

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

February 25, 2024 | msn.com

Kura Oncology (KURA) Price Target Increased by 6.63% to 30.77

February 22, 2024 | finance.yahoo.com

Kura Oncology to Participate in Three Upcoming Investor Conferences

February 22, 2024 | globenewswire.com

Kura Oncology to Participate in Three Upcoming Investor Conferences

See More Headlines

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KURA
CUSIP: N/A
CIK: 1422143
Web: www.kuraoncology.com
Phone: (858) 500-8800
Fax: N/A
Employees: 142
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $28.28
High Stock Price Target: $37.00
Low Stock Price Target: $10.50
Potential Upside/Downside: +59.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-152,630,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -36.30%
Return on Assets: -33.12%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 12.26
Quick Ratio: 12.26

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.35 per share
Price / Book: 3.30

Miscellaneous

Outstanding Shares: 76,180,000
Free Float: 72,067,000
Market Cap: $1.35 billion
Optionable: Optionable
Beta: 0.85

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Troy Edward Wilson J.D. (Age 55)
Ph.D., Chairman, CEO & President
Comp: $1.06M
Ms. Kathleen Ford (Age 77)
Chief Operating Officer
Comp: $754.24k
Dr. Stephen Dale M.D. (Age 52)
Chief Medical Officer
Comp: $684.41k
Mr. Thomas Doyle (Age 53)
Senior Vice President of Finance & Accounting
Mr. Pete De Spain
Executive Vice President of Investor Relations & Corporate Communications
Ms. Teresa Brophy Bair Esq. (Age 53)
J.D., Chief Legal Officer & Corporate Secretary
Dr. Roger Bakale Ph.D.
Senior Vice President of Manufacturing & Supply Chain
Ms. Maureen Clancy M.B.A.
VP and Global Head of Program Leadership & Project Management
Dr. Mollie Leoni M.D.
Executive Vice President of Clinical Development
Mr. Brian T. Powl M.B.A. (Age 50)
M.S., Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KURA shares.
View KURA analyst ratings or view top-rated stocks.
What is Kura Oncology's stock price target for 2024?: 8 analysts have issued twelve-month price objectives for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they predict the company's share price to reach $28.28 in the next year. This suggests a possible upside of 63.7% from the stock's current price.
View analysts price targets for KURA or view top-rated stocks among Wall Street analysts.
How have KURA shares performed in 2024?: Kura Oncology's stock was trading at $14.38 on January 1st, 2024. Since then, KURA shares have increased by 20.1% and is now trading at $17.27.
View the best growth stocks for 2024 here.
When is Kura Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our KURA earnings forecast.
How were Kura Oncology's earnings last quarter?: Kura Oncology, Inc. (NASDAQ:KURA) issued its earnings results on Tuesday, February, 27th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.01. During the same quarter in the previous year, the business earned ($0.49) earnings per share.

What ETFs hold Kura Oncology's stock?: ETFs with the largest weight of Kura Oncology (NASDAQ:KURA) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).ALPS Medical Breakthroughs ETF (SBIO).
What other stocks do shareholders of Kura Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).
Who are Kura Oncology's major shareholders?: Kura Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.24%) and Saxon Interests Inc. (0.01%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Teresa Brophy Bair, Thomas James Doyle, Thomas Malley and Troy Edward Wilson.
View institutional ownership trends.
How do I buy shares of Kura Oncology?: Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KURA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kura Oncology (KURA) Stock Price, News & Analysis

Kura Oncology MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Kura Oncology Stock (NASDAQ:KURA)

KURA Stock Price History

KURA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KURA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™